Last reviewed · How we verify
MGC026 Dose Escalation — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
MGC026 Dose Escalation (MGC026 Dose Escalation) — MacroGenics.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| MGC026 Dose Escalation TARGET | MGC026 Dose Escalation | MacroGenics | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- MGC026 Dose Escalation CI watch — RSS
- MGC026 Dose Escalation CI watch — Atom
- MGC026 Dose Escalation CI watch — JSON
- MGC026 Dose Escalation alone — RSS
Cite this brief
Drug Landscape (2026). MGC026 Dose Escalation — Competitive Intelligence Brief. https://druglandscape.com/ci/mgc026-dose-escalation. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing